Literature DB >> 17284184

Omega-conotoxin CVIB differentially inhibits native and recombinant N- and P/Q-type calcium channels.

Leonid Motin1, Takahiro Yasuda, Christina I Schroeder, Richard J Lewis, David J Adams.   

Abstract

Omega-conotoxins are routinely used as selective inhibitors of different classes of voltage-gated calcium channels (VGCCs) in excitable cells. In the present study, we examined the potent N-type VGCC antagonist omega-conotoxin CVID and non-selective N- and P/Q-type antagonist CVIB for their ability to block native VGCCs in rat dorsal root ganglion (DRG) neurons and recombinant VGCCs expressed in Xenopus oocytes. Omega-conotoxins CVID and CVIB inhibited depolarization-activated whole-cell VGCC currents in DRG neurons with pIC50 values of 8.12 +/- 0.05 and 7.64 +/- 0.08, respectively. Inhibition of Ba2+ currents in DRG neurons by CVID (approximately 66% of total) appeared to be irreversible for > 30 min washout, whereas Ba2+ currents exhibited rapid recovery from block by CVIB (> or = 80% within 3 min). The recoverable component of the Ba2+ current inhibited by CVIB was mediated by the N-type VGCC, whereas the irreversibly blocked current (approximately 22% of total) was attributable to P/Q-type VGCCs. Omega-conotoxin CVIB reversibly inhibited Ba2+ currents mediated by N- (Ca(V)2.2) and P/Q- (Ca(V)2.1), but not R- (Ca(V)2.3) type VGCCs expressed in Xenopus oocytes. The alpha2delta1 auxiliary subunit co-expressed with Ca(V)2.2 and Ca(V)2.1 reduced the sensitivity of VGCCs to CVIB but had no effect on reversibility of block. Determination of the NMR structure of CVIB identified structural differences to CVID that may underlie differences in selectivity of these closely related conotoxins. Omega-conotoxins CVIB and CVID may be useful as antagonists of N- and P/Q-type VGCCs, particularly in sensory neurons involved in processing primary nociceptive information.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284184     DOI: 10.1111/j.1460-9568.2006.05299.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Spinal actions of ω-conotoxins, CVID, MVIIA and related peptides in a rat neuropathic pain model.

Authors:  A Jayamanne; H J Jeong; C I Schroeder; R J Lewis; M J Christie; C W Vaughan
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 3.  Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Ca(V) 2.2) calcium channels.

Authors:  David J Adams; Brid Callaghan; Géza Berecki
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.

Authors:  G Berecki; N L Daly; Y H Huang; S Vink; D J Craik; P F Alewood; D J Adams
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

5.  Novel analgesic ω-conotoxins from the vermivorous cone snail Conus moncuri provide new insights into the evolution of conopeptides.

Authors:  Silmara R Sousa; Jeffrey R McArthur; Andreas Brust; Rebecca F Bhola; K Johan Rosengren; Lotten Ragnarsson; Sebastien Dutertre; Paul F Alewood; Macdonald J Christie; David J Adams; Irina Vetter; Richard J Lewis
Journal:  Sci Rep       Date:  2018-09-07       Impact factor: 4.379

6.  Expression and pharmacology of endogenous Cav channels in SH-SY5Y human neuroblastoma cells.

Authors:  Silmara R Sousa; Irina Vetter; Lotten Ragnarsson; Richard J Lewis
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

Review 7.  Venom peptides as a rich source of cav2.2 channel blockers.

Authors:  Silmara R Sousa; Irina Vetter; Richard J Lewis
Journal:  Toxins (Basel)       Date:  2013-02-04       Impact factor: 4.546

8.  Novel ω-conotoxins from C. catus reverse signs of mouse inflammatory pain after systemic administration.

Authors:  Mahsa Sadeghi; Swetha S Murali; Richard J Lewis; Paul F Alewood; Sarasa Mohammadi; MacDonald J Christie
Journal:  Mol Pain       Date:  2013-10-20       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.